Revance Therapeutics has appointed Caryn McDowell as senior vice president, general counsel and corporate secretary - a newly created position - effective May 1.
In her new role, McDowell reports to president and CEO Dan Browne, and will lead all legal, governance and compliance initiatives for the Newark, California-based biotechnology company. The company has until now used outside counsel, according to a spokesperson.
She joined Revance from Cytokinetics, where she served as general counsel, chief compliance officer and secretary. In that role, she was involved in creating policies and practices for US Food and Drug Administration and European Medicines Agency product approval and commercialization, as well as managing alliances and financing transactions.
Previously, she was vice president, deputy general counsel and assistant corporate secretary at InterMune, where she helped prepare for the US approval and launch of the medication Esbrie and the company’s acquisition by Roche. Earlier in her career, she served in legal roles at Onyx Pharmaceuticals, Genentech and Millennium Pharmaceuticals.
‘Caryn brings extensive legal experience in the biopharma and healthcare sectors, advising companies developing and commercializing novel drug products,’ Browne says in a statement. ‘During her career, she has played a pivotal role managing a broad range of partnering relationships, strategic alliances and financing initiatives critical to the success and growth of dynamic biotechnology companies.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
